All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the AML Hub spoke to Alexander Perl, University of Pennsylvania, Philadelphia, US. We Asked, What are the future prospects for FLT3 mutated acute myeloid leukemia (AML)?
What are the future prospects for FLT3 mutated AML?
Perl begins by outlining the standard of care for patients being treated intensely with newly diagnosed AML and upcoming studies investigating FLT3 inhibitors such as midostaurin, sorafenib, quizartinib, and gilteritinib. He goes on to discuss treatment prospects for patients ineligible for intensive chemo and post transplant maintenance. Finally, he highlights the importance of upcoming study MORPHO, which investigates gilteritinib as posttransplant maintenance.
How could new treatment combinations improve outcomes in TP53 mutant AML?
During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the AML Hub spoke to Naval Daver, MD Anderson Cancer Center, Houston, US. We asked, How could new...
EHA 2019 | What effect does gilteritinib have on FLT3 mutated relapsed/refractory AML?
Alexander Perl presented the data from the ADMIRAL phase III trial of gilteritinib, a selective FLT3 inhibitor, for relapsed or refractory (R/R) acute myeloid...
Subscribe to get the best content related to AML delivered to your inbox